Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Receivables - Net: 2020-2023

Historic Receivables - Net for Relay Therapeutics (RLAY) over the last 3 years, with Sep 2023 value amounting to $211,000.

  • Relay Therapeutics' Receivables - Net fell 12.45% to $211,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $211,000, marking a year-over-year decrease of 12.45%. This contributed to the annual value of $306,000 for FY2022, which is 24.07% down from last year.
  • Relay Therapeutics' Receivables - Net amounted to $211,000 in Q3 2023, which was up 170.51% from $78,000 recorded in Q2 2023.
  • In the past 5 years, Relay Therapeutics' Receivables - Net registered a high of $75.0 million during Q4 2020, and its lowest value of $78,000 during Q2 2023.
  • In the last 3 years, Relay Therapeutics' Receivables - Net had a median value of $282,500 in 2021 and averaged $316,500.
  • As far as peak fluctuations go, Relay Therapeutics' Receivables - Net plummeted by 99.46% in 2021, and later rose by 6.32% in 2023.
  • Over the past 4 years, Relay Therapeutics' Receivables - Net (Quarterly) stood at $75.0 million in 2020, then plummeted by 99.46% to $403,000 in 2021, then declined by 24.07% to $306,000 in 2022, then decreased by 12.45% to $211,000 in 2023.
  • Its Receivables - Net was $211,000 in Q3 2023, compared to $78,000 in Q2 2023 and $286,000 in Q1 2023.